Funds holding Quince Therapeutics Inc
ISIN US22053A3059 · United States
- Fund holders
- 1
- Of which ETFs
- 0 1 other fund
- Value held
- 219.1K $
- Share of capital
- 1.2 % of 1M shares on Aug 7, 2026
A single tracked fund declares this company. So these figures do not say who owns it.
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 12,044 | 219.1K $ | 0.00 % | 1.18 % | as of Jun 30, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 0.00 % | as of Jun 30, 2026 ↗ |
Declared shareholders of Quince Therapeutics Inc
There are 5 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| BALYASNY ASSET MANAGEMENT L.P. and 4 others | 9.99 % | 97,699 | as of Jun 30, 2026 · SCHEDULE 13G |
| Cormorant Asset Management, LP and 1 other | 9.99 % | 108,029 | as of Jun 30, 2026 · SCHEDULE 13G |
| Ikarian Capital, LLC and 1 other | 9.00 % | 91,789 | as of Jun 30, 2026 · SCHEDULE 13G |
| Squadron Master Fund LP and 3 others | 5.60 % | 55,173 | as of Jul 28, 2026 · SCHEDULE 13G |
| Nantahala Capital Management, LLC and 2 others | 0.00 % | 0 | as of Jun 30, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Funds holding Quince Therapeutics Inc". https://titelia.com/en/stocks/quince-therapeutics-inc-US22053A3059